/

EVGN

Evogene Ltd.Closed

0.3902+0.00 +0.96%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

0.3850

Prev close

0.3865

Day range

0.37260.3990

52-week range

0.35001.49

Volume

87.44K0.06×

Mkt cap

6.17M

P/E ttm

—

Fwd P/E

-0.65

EPS ttm

-1.55

Div yield

0.00%

Earnings

Aug 18, 2026

From 52w high

−73.81%

Price Chart

Yahoo Finance · delayed

EVGNOct 13, 2026O 0.3900H 0.4000L 0.3700C 0.39000.0000 (0.00%)Vol 87.60K

SMA 500.5126
SMA 2000.7092

1Y change −69.77% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

EVGN Evogene Ltd. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.14%
1 month: −18.75%
3 months: −18.75%
6 months: −52.44%
Year to date: −64.55%
1 year: −69.53%

Valuation & ownership

Market cap: 6.17M
Enterprise value: 7.12M
P/E (ttm): —
Forward P/E: -0.65
PEG ratio: —
Price / book: —
Price / sales (ttm): 3.72
EV / EBITDA: -0.51
EPS (ttm): -1.55
EPS (forward): -0.6000
Beta (5y monthly): 0.72
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 15.80M
Float: 12.38M
Short % of float: 5.94%
Short ratio (days): 0.28
Held by insiders: 24.39%
Held by institutions: 5.57%
Avg volume (3m): 1.49M
50-day average: 0.5156
200-day average: 0.7125
52-week change: −69.53%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 39.0
vs 50-day SMA: −23.92%
vs 200-day SMA: −45.01%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 12.49%
Realised vol (20d, ann.): 89.0%
From 52-week high: −73.83%
From 52-week low: +11.43%

ANR

Analyst Consensus

1 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

2.15

+451.00% implied

Low 2.15Median 2.15High 2.15

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About Evogene Ltd.

Yahoo Finance profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Sector: Healthcare
Industry: Biotechnology
Employees: 38
Headquarters: Rehovot, Israel
Website: evogene.com
Officers: Mr. Ofer Haviv CPA CEO, President, CFO & Director
Mr. Yoash Zohar Chief Executive Officer of Casterra Ag Ltd.
Dr. Dan Jacob Gelvan Ph.D. Chief Executive Officer of Ag Plenus Ltd.

SEAS

Seasonality · EVGN

2010–2026 · monthly returns

Strongest month Dec +5.95%Weakest month Mar −8.76%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-8.2	-12.9	-12.5	1.3	-9.0	-38.0	6.8	14.9	-25.9	-2.5			−64.5%
2025	-16.0	-7.0	-14.4	-9.6	-3.5	17.4	-6.2	4.2	-8.8	10.5	-15.9	3.8	−41.2%
2024	-9.5	19.7	-17.6	-6.7	7.1	-13.3	-25.7	-31.9	-6.7	-25.7	-29.4	16.1	−77.7%
2023	14.3	-5.0	-17.1	-6.3	1.7	78.3	0.0	-30.8	-20.3	-18.6	35.4	29.2	+20.0%
2022	-15.2	-6.5	0.0	-18.5	-10.4	-18.9	6.5	26.8	-20.2	-12.0	-13.7	11.1	−57.3%
2021	30.2	-4.1	-14.1	-13.5	-20.2	-1.7	-16.4	4.9	-12.0	-1.1	-23.8	-17.6	−65.1%
2020	3.9	-15.8	-11.3	-5.1	-8.0	-2.9	4.0	99.0	91.3	-31.3	27.6	35.4	+209.2%
2019	16.7	-6.9	-14.9	12.6	-25.2	4.5	-9.3	11.0	-2.5	1.3	-15.0	11.8	−23.2%
2018	19.2	6.3	-18.3	-2.5	-1.3	-6.5	0.7	-4.9	13.5	-13.5	-4.5	-23.0	−35.5%
2017	-1.8	2.8	3.9	0.2	-4.9	-0.8	-4.3	-3.9	-4.5	-4.5	-9.2	-20.3	−39.8%
2016	-18.0	8.2	-8.8	14.6	-8.3	-8.8	10.3	-3.9	-3.5	-5.8	-7.2	-8.6	−36.6%
2015	-8.8	19.8	-12.3	13.4	-2.3	-9.5	0.2	-3.8	-3.2	-8.7	-11.2	20.3	−12.6%
2014	-10.8	8.0	0.6	-8.4	-2.1	-4.1	-18.2	-2.2	0.4	-13.1	-19.5	0.1	−53.1%
2013	9.8	-3.1	1.0	0.0	10.9	14.3	-10.2	0.0	32.2	7.2	4.5	15.4	+109.0%
2012	0.7	7.7	-7.9	11.0	-6.6	0.0	-2.1	3.4	-12.8	5.3	17.7	1.1	+14.6%
2011	-5.4	-2.1	-0.2	0.0	-0.6	0.0	0.0	-22.5	0.0	0.0	-1.0	3.8	−26.8%
2010											0.0	16.4	+16.4%

INSD

Insider Activity · EVGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 10, 2026	Recanati Leon YehudaDirector	Purchase at price 0.64 per share.	460K	$292.10K
Aug 3, 2026	Recanati Leon YehudaDirector	Purchase at price 0.65 per share.	800K	$520.00K
Jun 3, 2026	Tarcic Gabi Ph.D.Officer	Purchase at price 0.60 per share.	1.1K	$677

EVGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

EVGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Evogene Ltd.

Seasonality · EVGN

Insider Activity · EVGN

Congress Trades · EVGN

Investors Holding EVGN

Investors Holding EVGN

Congress Trades · EVGN

Insider Activity · EVGN

Seasonality · EVGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Evogene Ltd.

Earnings & Dividends

News